Eurofins Expands into Hygiene Testing in Hospitals with the Acquisition of Biotech-Germande
03 December 2015 - 5:30PM
Business Wire
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), the global leader in
bioanalytical testing of food, pharmaceuticals and the environment,
announces that it has signed an agreement to acquire
Biotech-Germande SAS (BG), one of the leading players in the
environmental clinical testing and hospital hygiene market, as well
as in medical device evaluation in France.
Located in Marseille, BG employs 40 staff, and has established a
strong reputation over the last 15 years, as a reference in
healthcare and hospital hygiene. The company conducts testing of
water, air, surfaces and endoscopes in hospitals and healthcare
facilities, as well as evaluation of medical devices for
manufacturers. BG has seen, and expects to continue to post, strong
growth driven primarily by hospitals outsourcing mandatory
infectious controls, and increasingly stringent regulations for
independent testing of medical devices.
The acquisition complements Eurofins’ growing footprint in the
testing market for the healthcare sector in France, and allows the
Group to create a more compelling portfolio of services for
hospitals and other healthcare facilities served by Bioaccess and
Biomnis. In return, BG should gain access to Eurofins’
infrastructure, including the Group’s complete testing portfolio
for hospitals and drug & medical device manufacturers, and
could leverage Eurofins’ extensive network to further accelerate
growth. Eurofins’ existing footprint in water testing, as well as
the Group’s unparalleled capabilities in microbiology, should allow
BG to expand its market reach or accelerate share gains in its
existing markets.
Comment from Dr. Gilles Martin, Eurofins CEO:
“Biotech-Germande strengthens Eurofins’ service offering to
hospitals in a key area for patients’ safety, and reinforces our
growing footprint in medical device testing. We look forward to
strengthening BG’s position in its market by providing them access
to the Group’s complete range of capabilities, as well as client
base.”
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food, environment and
pharmaceutical products testing. It is also one of the global
market leaders in agroscience, genomics, discovery pharmacology and
central laboratory services. In addition, Eurofins is one of the
key emerging players in specialty clinical diagnostic testing in
Europe and the USA.
With 20,000 staff in around 200 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products, as well as for innovative clinical
diagnostic. The Group provides its customers with high-quality
services, accurate results on time and expert advice by its highly
qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151202006194/en/
For more information, please visit
www.eurofins.com or contact:Eurofins Investor
RelationsPhone: +32-2-766 1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024